An estimated 30-50%, and possible 60%, of patients with inflammatory bowel disease (IBD) turn to complementary and alternative medicines (CAM’s) to ease symptoms and exert more control over their treatment. Very few studies have evaluated CAM’s, and many of the studies were small, poorly designed, and uncontrolled. Predictors of CAM use include dissatisfaction with conventional therapies,
